Literature DB >> 20350831

OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria.

Marjan Huizing1, Heidi Dorward, Lien Ly, Enriko Klootwijk, Robert Kleta, Flemming Skovby, Wuhong Pei, Benjamin Feldman, William A Gahl, Yair Anikster.   

Abstract

3-Methylglutaconic aciduria type III (3-MGCA type III), caused by recessive mutations in the 2-exon gene OPA3, is characterized by early-onset bilateral optic atrophy, later-onset extrapyramidal dysfunction, and increased urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid. Here we report the identification of a novel third OPA3 coding exon, the apparent product of a segmental duplication event, resulting in two gene transcripts, OPA3A and OPA3B. OPA3A deficiency (as in optic atrophy type 3) causes up-regulation of OPA3B. OPA3 protein function remains unknown, but it contains a putative mitochondrial leader sequence, mitochondrial sorting signal and a peroxisomal sorting signal. Our green fluorescent protein tagged OPA3 expression studies found its localization to be predominantly mitochondrial. These findings thus place the cellular metabolic defect of 3-MGCA type III in the mitochondrion rather than the peroxisome and implicate loss of OPA3A rather than gain of OPA3B in disease etiology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350831      PMCID: PMC2872056          DOI: 10.1016/j.ymgme.2010.03.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

1.  3-Methylglutaconic aciduria: a marker for as yet unspecified disorders and the relevance of prenatal diagnosis in a 'new' type ('type 4').

Authors:  D Chitayat; J Chemke; K M Gibson; O A Mamer; J B Kronick; J J McGill; B Rosenblatt; L Sweetman; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  [An OPA3 gene mutation is responsible for the disease associating optic atrophy and cataract with extrapyramidal signs].

Authors:  C Verny; P Amati-Bonneau; F Dubas; Y Malthiéry; P Reynier; D Bonneau
Journal:  Rev Neurol (Paris)       Date:  2005-04       Impact factor: 2.607

3.  Iraqi-Jewish kindreds with optic atrophy plus (3-methylglutaconic aciduria type 3) demonstrate linkage disequilibrium with the CTG repeat in the 3' untranslated region of the myotonic dystrophy protein kinase gene.

Authors:  A Nystuen; H Costeff; O N Elpeleg; N Apter; B Bonné-Tamir; H Mohrenweiser; N Haider; E M Stone; V C Sheffield
Journal:  Hum Mol Genet       Date:  1997-04       Impact factor: 6.150

4.  OPA3 mutation screening in patients with unexplained 3-methylglutaconic aciduria.

Authors:  K Neas; B Bennetts; K Carpenter; R White; E P Kirk; M Wilson; R Kelley; I Baric; J Christodoulou
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 5.  Optic atrophies in metabolic disorders.

Authors:  Marjan Huizing; Brian P Brooks; Yair Anikster
Journal:  Mol Genet Metab       Date:  2005-09-27       Impact factor: 4.797

6.  Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations.

Authors:  Marc Ferré; Dominique Bonneau; Dan Milea; Arnaud Chevrollier; Christophe Verny; Hélène Dollfus; Carmen Ayuso; Sabine Defoort; Catherine Vignal; Xavier Zanlonghi; Jean-Francois Charlin; Josseline Kaplan; Sylvie Odent; Christian P Hamel; Vincent Procaccio; Pascal Reynier; Patrizia Amati-Bonneau
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

7.  3-methylglutaconic acidemia in Smith-Lemli-Opitz syndrome.

Authors:  R I Kelley; L Kratz
Journal:  Pediatr Res       Date:  1995-05       Impact factor: 3.756

8.  A missense mutation in the murine Opa3 gene models human Costeff syndrome.

Authors:  Vanessa J Davies; Kate A Powell; Kathryn E White; Wanfen Yip; Vanessa Hogan; Andrew J Hollins; Jennifer R Davies; Malgorzata Piechota; David G Brownstein; Stuart J Moat; Philip P Nichols; Michael A Wride; Michael E Boulton; Marcela Votruba
Journal:  Brain       Date:  2008-02       Impact factor: 13.501

9.  3-Methylglutaconic aciduria in the Iraqi-Jewish 'optic atrophy plus' (Costeff) syndrome.

Authors:  O N Elpeleg; H Costeff; A Joseph; Y Shental; R Weitz; K M Gibson
Journal:  Dev Med Child Neurol       Date:  1994-02       Impact factor: 5.449

10.  Hidden localization motifs: naturally occurring peroxisomal targeting signals in non-peroxisomal proteins.

Authors:  Georg Neuberger; Markus Kunze; Frank Eisenhaber; Johannes Berger; Andreas Hartig; Cecile Brocard
Journal:  Genome Biol       Date:  2004-11-30       Impact factor: 13.583

View more
  13 in total

Review 1.  Mitochondria: the next (neurode)generation.

Authors:  Eric A Schon; Serge Przedborski
Journal:  Neuron       Date:  2011-06-23       Impact factor: 17.173

2.  A model of Costeff Syndrome reveals metabolic and protective functions of mitochondrial OPA3.

Authors:  Wuhong Pei; Lisa E Kratz; Isa Bernardini; Raman Sood; Tohei Yokogawa; Heidi Dorward; Carla Ciccone; Richard I Kelley; Yair Anikster; Harold A Burgess; Marjan Huizing; Benjamin Feldman
Journal:  Development       Date:  2010-08-01       Impact factor: 6.868

Review 3.  Mitochondrial disorders and the eye.

Authors:  Samantha A Schrier; Marni J Falk
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

Review 4.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 5.  Mitochondrial Membrane Dynamics and Inherited Optic Neuropathies.

Authors:  Eleni Bagli; Anastasia K Zikou; Niki Agnantis; Georgios Kitsos
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

6.  Clinical and molecular genetic findings in autosomal dominant OPA3-related optic neuropathy.

Authors:  Panagiotis I Sergouniotis; Rahat Perveen; Dawn L Thiselton; Konstantinos Giannopoulos; Marios Sarros; Jennifer R Davies; Susmito Biswas; Alec M Ansons; Jane L Ashworth; I Christopher Lloyd; Graeme C Black; Marcela Votruba
Journal:  Neurogenetics       Date:  2014-08-27       Impact factor: 2.660

Review 7.  Disturbed mitochondrial dynamics and neurodegenerative disorders.

Authors:  Florence Burté; Valerio Carelli; Patrick F Chinnery; Patrick Yu-Wai-Man
Journal:  Nat Rev Neurol       Date:  2014-12-09       Impact factor: 42.937

8.  Mitochondrial fusion proteins and human diseases.

Authors:  Michela Ranieri; Simona Brajkovic; Giulietta Riboldi; Dario Ronchi; Federica Rizzo; Nereo Bresolin; Stefania Corti; Giacomo P Comi
Journal:  Neurol Res Int       Date:  2013-05-27

Review 9.  The 3-methylglutaconic acidurias: what's new?

Authors:  Saskia B Wortmann; Leo A Kluijtmans; Udo F H Engelke; Ron A Wevers; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2010-09-30       Impact factor: 4.982

10.  Two novel compound heterozygous mutations in OPA3 in two siblings with OPA3-related 3-methylglutaconic aciduria.

Authors:  Christina Lam; Linda K Gallo; Richard Dineen; Carla Ciccone; Heidi Dorward; George E Hoganson; Lynne Wolfe; William A Gahl; Marjan Huizing
Journal:  Mol Genet Metab Rep       Date:  2014-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.